AstraZeneca (LON:AZN) Sets New 52-Week High – Still a Buy?

AstraZeneca PLC (LON:AZN) shares reached a new 52-week high on Friday . The company traded as high as £154.74 and last traded at £135.85, with a volume of 422522813 shares traded. The stock had previously closed at £135.48.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Jefferies Financial Group restated a “buy” rating and issued a £150 price target on shares of AstraZeneca in a research note on Monday, November 10th. Berenberg Bank raised their target price on shares of AstraZeneca from £142 to £145 and gave the stock a “buy” rating in a report on Tuesday, October 21st. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a £140 price target on shares of AstraZeneca in a research note on Thursday, December 4th. Finally, Shore Capital restated a “buy” rating and set a £145 price objective on shares of AstraZeneca in a research note on Thursday, November 6th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of £138.

AstraZeneca Stock Up 0.9%

The firm has a 50 day simple moving average of £132.02 and a two-hundred day simple moving average of £118.84. The stock has a market capitalization of £211.95 billion, a P/E ratio of 22.71, a PEG ratio of 0.86 and a beta of 0.17. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.